Evidence from randomized open-label trials suggests that rapid/short-acting insulin analogues (SAIAs), such as insulin lispro, are more effective than the conventional RHI in terms of reduced postprandial plasma glucose excursions [1,3–8] and reductions in the frequency of severe and nocturnal hypoglycaemia [9–11] as a result of improved pharmacokinetics [12]. This evidence concerns the gene INS and Hypoglycemia.